Location History:
- Coleraine Co. Londonderry, GB (2008)
- Coleraine, IE (2011)
- Portrush, GB (2005 - 2015)
- Portstewart, GB (2018)
- Coleraine, GB (2019 - 2023)
Company Filing History:
4 out of 7 
4 out of 36 
2 out of 5 Years Active: 2005-2023
Title: Innovations by Peter Raymond Flatt
Introduction
Peter Raymond Flatt is a notable inventor based in Portrush, GB. He has made significant contributions to the field of medical treatments, particularly in the area of diabetes and related conditions. With a total of 10 patents to his name, Flatt's work has the potential to impact many lives.
Latest Patents
Flatt's latest patents include innovative compositions for the treatment of diabetes, specifically targeting type-2 diabetes, obesity, and metabolic syndrome. One of his inventions focuses on a composition that includes diindolylmethane, indole-3-carbinol, embelin, [6]-gingerol, and [6]-shogaol, or combinations thereof. This composition aims to provide effective treatment options for individuals suffering from these conditions. Another significant patent involves an esculentin-2CHa peptide and its analogs, which are designed for the treatment of diabetes, insulin resistance, obesity, and hypercholesterolemia. This patent also includes a pharmaceutical composition that utilizes these peptides for medicinal purposes.
Career Highlights
Throughout his career, Flatt has worked with various organizations, including Uutech Limited and the University of Ulster. His experience in these institutions has allowed him to develop and refine his innovative ideas, contributing to advancements in medical science.
Collaborations
Flatt has collaborated with notable colleagues such as Finbarr Paul Mary O'Harte and Christian Holscher. These partnerships have likely enhanced his research and development efforts, leading to the successful creation of his patents.
Conclusion
Peter Raymond Flatt's contributions to the field of diabetes treatment through his innovative patents demonstrate his commitment to improving health outcomes. His work continues to pave the way for new therapeutic options in the medical community.